Company Focus

Bayer

Latest Bayer News

Bayer’s Nubeqa bags third indication in EU
Pharmaceutical
The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT), for a third therapeutic indication.   21 July 2025


Latest News & Features of interest to Bayer

Latest Ones To Watch News of interest to Bayer

Ones to Watch Companies of interest to Bayer

Reset all filters
Refine Search